Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03630913
Other study ID # ICO-N-2018-03
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 8, 2019
Est. completion date October 2023

Study information

Verified date April 2022
Source Institut Cancerologie de l'Ouest
Contact JEAN-MARC CLASSE, MD
Phone +33240679910
Email Jean-Marc.Classe@ico.unicancer.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Sentinel lymph node dissection (SLND) after NAC, aimed to reduce the rate of unnecessary axillary lymphadenectomy, is not a standard of care in case of patient with previously involved node before NAC because of a too high false negative rate (FNR). Clinical consequences of FNR of SLND after NAC are currently unknown. Consequently, contrary to adjuvant setting, a risk of SLND false negative case after NAC is not acceptable. GANEA3 aims to evaluate the results of an innovative multiparametric strategy combining (1) an identification before chemotherapy of a lymph node involvement using a metal clip and then its analysis after treatment, (2) the analysis of sentinel lymph node (SLN) after NAC, and (3) analysis of biological parameters of breast tumor before and after NAC, to predict axillary status after NAC. This will identify patients with initial lymph node involvement who could benefit from SLN after NAC without additional axillary dissection with a very low FNR (≤1%). The most "pathological" metastatic lymph node will be identified with a metal clip under ultrasound. They will then receive a NAC before breast and axillary surgery. An assessment of the NAC response at the breast and axillary will be performed by imagery. Then, all patients undergo the resection of the tagged axillary node with the metal clip, SLN detection and biopsy and a complementary axillary lymphadenectomy.


Description:

GANEA3 is a prospective multicenter diagnostic study assessing the benefit of targeting initial involved node in complement to SLND and breast tumor characteristics to predict axillary status after NAC. The diagnostic performances of this strategy will be primarily assessed by the decrease of the FNR with the combined strategy compared to SLND alone. The primary objective is to evaluate the interest of identifying, before NAC, the initial involved lymph node to improve the prediction of axillary status after NAC. The main secondary objectives are : - To assess the feasibility, at the time of the surgery, of the identification and resection of the initially involved lymph node, tagged with the metal clip before NAC ; - To evaluate the complications related to the setting up of the metal clip for the identification of a lymph node metastatic ; - To evaluate the interest and impact of immunohistochemical analysis of tagged lymph node and SLN ; Patients treated for a large early breast cancer (BC) needing NAC undergo axillary sonography assessment routinely performed to seek suspicious nodes. When several suspicious nodes are found only the worst is chosen. A fine needle aspiration is performed to allow cytological examination (biopsy is optional) of the suspicious node. In case of proven axillary involvement, the patient is informed about GANEA 3 study in order to be included. At this step the patient must accept the study and sign the consent form. The involved node is then tagged (with a metal clip) under sonography. In case of multiple suspicious nodes, the radiologist must choose the worst node in order to tag only one involved node. Then, then patients will perform their chemotherapy. The choice of NAC regimen is let at the discretion of each participating team. After NAC, breast tumor size and axillary assessment are performed. Breast and axillary surgery are performed during the same procedure, 4 to 6 weeks after completion of NAC. Breast surgery can be conservative or radical. All patients undergo the resection of the tagged axillary node, SLN biopsy and a complementary axillary lymphadenectomy.


Recruitment information / eligibility

Status Recruiting
Enrollment 385
Est. completion date October 2023
Est. primary completion date October 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients = 18 years old 2. Initial diagnosis of operable invasive breast carcinoma 3. Histologically proven axillary metastasis (cytology or biopsy) before NAC 4. Patient included in a therapeutic approach of neoadjuvant chemotherapy 5. Procedure for the detection of sentinel lymph node by isotopic method +/- colorimetric 6. Information of the patient and obtaining written consent, signed by the patient and the investigator 7. Affiliated patient or beneficiary of the social security Exclusion Criteria: 1. pT4d (inflammatory breast cancer) 2. Metastatic breast cancer 3. Any prior chemotherapy for contralateral breast cancer 4. Local relapse of breast cancer 5. Axillary metastasis not histologically proven before NAC 6. Allergy known to the 2 detection products (Blue and radioactive tracer) 7. Pregnant or lactating woman 8. Neo Adjuvant chemotherapy contraindicated 9. Patient protected or under guardianship or unable to give consent 10. Impossibility of submitting to the medical examination for geographical, social or psychological

Study Design


Intervention

Procedure:
Tagged axillary metastatic node
First, initially metastatic lymph node is tagged with a metal clip under sonography. Then, patients receive NAC before surgery. Breast surgery (conservative or radical) and axillary surgery are performed during the same procedure, 4 to 6 weeks after completion of NAC. SLN isotope detection is performed with or without blue dye. All patients undergo the resection of the tagged axillary node, SLN biopsy and a complementary axillary lymphadenectomy.

Locations

Country Name City State
France ICO - Site ANGERS Angers
France Institut Bergonié Bordeaux
France CHU Brest Brest
France Centre Jean Perrin Clermont-Ferrand
France Centre Georges Francoise Leclerc Dijon
France Oscar Lambret Lille
France Centre Léon Bérard Lyon
France Institut Paoli Calmettes Marseille
France Institut de Cancérologie de Montpellier Montpellier
France Anne-Sophie Georges BATS Paris
France APHP - Pitié Salpétrière Paris
France Hôpital St JOSEPH Paris
France Centre Jean Godinot Reims
France Céline RENAUDEAU Saint Herblain
France CURIE Saint-Cloud
France CHP St GREGOIRE Saint-Grégoire
France IUCT-O Toulouse
France Institut de Cancérlogie de Lorraine Vandœuvre-lès-Nancy

Sponsors (2)

Lead Sponsor Collaborator
Institut Cancerologie de l'Ouest Direction Générale de l'Offre de Soins

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary False negative rate number of cases of false prediction of absence of lymph node involvement to the total number of cases with metastatic lymph node. The rate of FN will be calculated for the involved lymph node tagged with the metal clip, the sentinel node, and the both 30 days after surgery
Secondary Identification rate of involved lymph node tagged number of cases where the tagged lymph node with a metal clip node is identified during axillary surgery and analyzed in pathology on the total number of procedures 30 days after surgery
Secondary Resection rate of involved lymph node tagged number of cases where the tagged lymph node is resected during axillary surgery and analyzed in pathology on the total number of procedures 30 days after surgery
Secondary Complication rate number of complications related to the axillary lymph node tagging procedure on the total number of procedures 30 days after surgery
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03595592 - Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer Phase 3
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT06158217 - Effect of Ultrasound Combined With Microbubbles on Blood Perfusion in Invasive Breast Cancer
Active, not recruiting NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Phase 2
Completed NCT02773784 - Comparison of CNB and Surgical Specimens for ER, PgR, HER2 Status and Ki67 Index in Invasive Breast Cancer.
Recruiting NCT01509781 - Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study Phase 3
Completed NCT04478669 - Digital Breast Tomosynthesis (DBT) to Improve Assessment of Resection Margins in Invasive Breast Cancer
Recruiting NCT04553770 - Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer Phase 2
Recruiting NCT04677816 - Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients Phase 2
Terminated NCT01934335 - Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer Phase 2
Completed NCT00507611 - Axillary Lymph Node Status After Completion of Preoperative Neoadjuvant Systemic Chemotherapy in Patients N/A
Completed NCT00581750 - Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ
Completed NCT03304171 - Overall Diet Quality and Breast Cancer Risk N/A
Completed NCT03709186 - Radiomic Markers for Breast Cancer Metastasis and Treatment Response Using MRI
Terminated NCT03361800 - Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC Early Phase 1
Recruiting NCT04648904 - Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer Early Phase 1
Recruiting NCT06328465 - fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases N/A
Active, not recruiting NCT03109522 - Axillary Reverse Mapping (ARM) Technique N/A
Recruiting NCT03987555 - Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Recruiting NCT03497702 - Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer Phase 2